Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimized synthesis and characterization of highly reproducible carbon dots for bioimaging applications.

Colloids and surfaces. B, Biointerfaces·2025
Same author

Improving efficiency in a total hip arthroplasty program.

Journal of healthcare quality research·2025
Same author

<sup>131</sup>I-mIBG therapy in relapsed/refractory neuroblastoma: an old bridge to the future.

ESMO open·2025
Same author

An ancestral molecular response to nanomaterial particulates.

Nature nanotechnology·2023
Same author

Analysis of Poly(thiourethane) Covalent Adaptable Network through Broadband Dielectric Spectroscopy.

ACS applied polymer materials·2023
Same author

Exploring the relationship between bacterial genera and lipid metabolism in bovine rumen.

Animal : an international journal of animal bioscience·2022

Related Experiment Video

Updated: Jun 29, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

Amiodarone-induced thyrotoxicosis. A review.

M Piga1, A Serra, F Boi

  • 1Department of Nuclear Medicine and Endocrinology, University Policlinic, University of Cagliari, Cagliari, Italy. pigam@medicina.unica.it

Minerva Endocrinologica
|October 11, 2008
PubMed
Summary

Amiodarone-induced thyrotoxicosis (AIT) presents as two types: AIT I (autonomous function) and AIT II (destructive thyroiditis). Differentiating these forms is crucial for effective treatment, with sestamibi scintigraphy showing promise.

Related Experiment Videos

Last Updated: Jun 29, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

Area of Science:

  • Endocrinology
  • Cardiology
  • Nuclear Medicine

Background:

  • Amiodarone (AM), an anti-arrhythmic drug, is iodine-rich and can disrupt thyroid function.
  • Chronic AM use can lead to amiodarone-induced thyrotoxicosis (AIT), presenting as hypothyroidism or thyrotoxicosis.
  • AIT is classified into AIT I (iodine exacerbation of autonomous function) and AIT II (destructive thyroiditis).

Purpose of the Study:

  • To differentiate between AIT I and AIT II for appropriate therapeutic selection.
  • To evaluate the diagnostic utility of sestamibi thyroid scintigraphy in distinguishing AIT subtypes.
  • To review current treatment strategies for AIT.

Main Methods:

  • Differential diagnosis using radioiodine uptake (RAIU) and color-flow Doppler sonography (CFDS).
  • Evaluation of sestamibi MIBI thyroid scintigraphy for differentiating AIT I and AIT II.
  • Review of therapeutic approaches based on AIT subtype.

Main Results:

  • AIT I shows high, normal, or low but detectable RAIU, with increased vascularity on CFDS.
  • AIT II demonstrates consistently very low or undetectable RAIU and absent vascularity on CFDS.
  • Sestamibi scintigraphy revealed increased MIBI retention in AIT I and no significant uptake in AIT II.

Conclusions:

  • Sestamibi scintigraphy is a valuable tool for differentiating AIT I from AIT II.
  • Treatment for AIT I involves thionamides and potassium perchlorate; AIT II responds to glucocorticoids.
  • Management of indeterminate forms and severe cases may require combined therapies or surgery.